INTRODUCTION

Chikungunya virus (CHIKV) is a mosquito-transmitted
Alphavirus belonging to the family Togaviridae that formed the 2006 Asian outbreak [1] . The clinical manifestation of patients affected by the virus includes febrile fever and mild to severe arthralgia with or without rash in the skin [2] [3] [4] [5] . Although the Indian Ocean outbreak was transmitted through Aedes mosquitoes, a report suggested that Chikungunya virus could also be transmitted through the Anopheles stephensi mosquito [1, 6] . In addition, other vertebrates like monkeys act as reservoirs for Chikungunya virus. Chikungunya virus was first identified in mid-1950 in Tanzania. Here, it occurred during a sylvatic cycle in the sub-Saharan Africa. Later, it became endemic within an urban cycle in Asia [7] . The African sylvatic cycle was maintained in non-human animals, small mammals like bats and monkeys and in mosquitoes [8] . Even though serological tests show non-human primates are the main host for CHIKV, isolation studies confirm that Aedes mosquitoes are the main vectors for CHIKV transmission [9] . Three types of CHIKV genotype have been recognized namely Asian, western African and east-central-south African [7, 10] .
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Md. Rajdoula Rafe 1 virus, Mayaro virus, O'nyong-nyong virus, Ross River virus, Sindbis virus and Barmah Forest virus [13] . Viruses of the Alphavirus genus have common antigenic determinants [14, 15] . Although CHIKV was first identified in 1950 in Tanzania, the exact time of the virus's origination is still unknown. O'nyong-nyong virus (ONNV) resembles CHIKV closely and it caused an outbreak in Africa through Anopheles mosquitoes almost 100 years before CHIKV was identified [16] . According to the phylogenic data analysis and other relationships between CHIKV and ONNV, it is believed that these viruses have evolved in the region of sub-Saharan Africa; however, the exact region of origination is yet to be found. In Africa, CHIKV mostly infects humans in the rural area by a sylvatic transmission cycle. Infections in the urban area are thought to be caused due to human migration and traveling. In epidemic periods, humans act as main reservoirs. Aedes aegypti and Aedes albopictus are the two principal vectors that are responsible for the transmission of CHIKV [17, 18] . Monkeys, rodents, birds, and buffalos are also involved in the transmission cycle during the inter-epidemic periods, acting as reservoirs [19] .
Clinical Pathophysiology
Infection caused by CHIKV is highly similar to infection caused by dengue virus, thereby making it difficult to differentiate. A CHIKV incubation period usually occurs in the range of 1-12 days and the average range of incubation is 2-4 days [20] [21] [22] [23] [24] . The later period of incubation is symptomatic with the onset of fever, arthralgia, myalgia, headache and skin rash [20] [21] [22] [23] [24] . Although, most of the patients recover from arthralgia within 1-2 weeks after the onset of disorders, in some cases, the arthralgia may persist for several months to years [25] [26] [27] [28] [29] . Numerous studies have found long-lasting arthralgia in CHIKV affected patients [25] [26] [27] [28] [29] .
Recently, a study on the outbreak of CHIKV in Reunion Island reported that symptoms in affected people might take up to 14 days to appear after the onset of CHIKV. During these 14 days, two stages were recognized, namely the 'viral stage' from 1 to 4 days with decreasing viremia, and the 'convalescent stages' from day 5 to 14 without any detectable viremia. Between these two stages, the second stage showed slower clinical improvement than the first stage [30] .
Diagnosis
There are limited diagnostic measures and opportunities to identify CHIKV due to the lack of research and knowledge on this virus. Furthermore, a successful control method is yet to be identified to manage CHIKV outbreaks. As of fall 2013, there are an estimated 1.2 million suspected CHIKV patients, but among them, only 2% have been confirmed by laboratory diagnostics. The majority of the infections in humans were identified with the combination of RT-PCR and IgM ELISA techniques. However, due to high cost and limited availability, in the local areas where CHIKV infections were severe, the use of diagnostic tests turned out to be insufficient. Sissoko et al. employed a retrospective serological test after the outbreak in 2006, in Mayotte Island, and reported that fever in combination with polyarthralgia had 84% sensitivity, 74% positive predictive value and 84% negative predictive value [31] . In comparison with the dengue virus, CHIKV is mostly presented with arthralgia and rash, whereas dengue is presented with myalgia and leucopoenia [32] . Other reported symptoms more related to CHIKV are lymphopenia, increased liver enzymes, and increased creatinine levels [33, 34] .
A study suggested that the enzyme-linked immunosorbent assay ((HCAb IgG2 and IgG3) based on the camel antibody is a reliable and accurate technique for identifying Chikungunya virus infections [35] . The assay result showed high precision and coefficient of variation for intra-plate and inter-plate (5% and 8%, respectively) in both types of assays (HCAb IgG2 and IgG3).
The National Virology Laboratory of Nicaragua developed two IgM ELISA capture systems (MAC-ELISA) and two inhibitions ELISA methods (IEM) in 2014-2015 for the diagnosis of acute CHIKV infections and measurement of total antibodies that worked against CHIKV. Monoclonal antibodies and hyper-immune serum were used to develop the assay techniques. Herein, sensitivity of 95.7% and specificity of 88.95.9% were observed during clinical evaluation of the four assays, in comparison with the real-time RT-PCR (Reverse Transcription-Polymerase Chain Reaction) assay recommended by Centers for Disease Control (CDC) [36] .
A recent quantitative RT-PCR study based on a SYBR Green I showed a 10-fold increase in sensitivity than conventional RT-PCR [37] . In another report, to amplify the nsP2 region of the CHIKV genome, researchers used derivatives of DANP (2, 7-diamino-1, 8-naphthyridine)-labeled cytosine bulge hairpin primers, then measured the fluorescence emitted from DANP and primer complexes after PCRs [38] .
In a different study, IgM and IgG antibodies working against CHIKV were evaluated by using a specific ELISA technique in 604 patients. After comparing patients with CHIKV and without CHIKV, a statistical significance was observed for IgG and IgM (p <0.0001) [39] .
Treatment
Chikungunya usually resolves with time without any treatment because there is no approved antiviral treatment yet discovered. Symptoms like fever and pain can be treated with anti-pyretic and analgesic, for example, paracetamol. CHIKV induced arthralgia can also be treated with NSAIDs (Nonsteroidal anti-inflammatory drugs). Ribavirin is an antiviral drug that can act against various RNA viruses, but its activity against Alphaviruses is not well studied [40] . Recently, however, some classes of compounds have been found to be effective in inhibiting CHIKV replication by either targeting the virus or the host [41] .
Ravichandran and Manian report that ribavirin had moderate effects against the arthralgia caused by CHIKV. However, this report was based on a limited number of patients. To establish the effects of ribavirin against CHIKV associated diseases, an extensive study of this drug on a broad-spectrum analysis of CHIKV affected patients is required [42] . The availability of limited antiviral drugs and the destructive nature of the CHIKV suggest that vaccination will be the most effective way of treating CHIKV both in terms of cost and efficacy [43] .
Current Issues in Pharmacy and Medical Sciences
Prevention & Control
The vector is the most important factor to control in CHIKV epidemics, due to the lack of effective treatment options. Transmission control of CHIKV through managing the growth of the vector could be an effective approach against CHIKV. Hence, breeding sites of vectors should be controlled to eradicate the vector as routine larviciding in public catch basins can inhibit the transmission and potential epidemics of CHIKV. Public awareness is also necessary to eliminate vectors of CHIKV. Personal awareness like sleeve clothing, covering bed sites and windows with net and using repellents spray can also be applied for vector control.
Parricidal activities can be promoted by involving private citizens to reduce transmission of CHIKV [44] .
Vaccination: Usually, vaccines are highly effective for treating vector-borne diseases. As CHIKV spreads rapidly with high attacking rate, novel therapeutic agent will also be valuable [45] . A monoclonal antibody (dMAb) containing anti-Chikungunya virus encoding DNA plasmids was designed to use as a prophylaxis therapy. The monoclonal antibody was delivered through an electroporation-mediated delivery system and its efficacy and limitations against virus was compared against conventional vaccine and immunotherapy. After treating mice models, the dMAb neutralized CHIKV isolates rapidly and protected recipients from the virus. However, the combination of dMAb and CHIKV DNA vaccine gave a more rapid and longer lasting protection against CHIKV [46] .
Modification of specific viral sequences is another approach to attenuate CHIKV and it might act as a vaccination, for example, nucleolar localization sequence (NoLS) in capsid protein can be modified to attenuate CHIKV [47] . Herein, modification of CHIKV-NoLS demonstrated less replication in mice and mosquito. In addition, mice treated with modified CHIKV-NoLS showed no disease progression compared to the mice with normal virus. Immunized mice also showed protection against other viruses like CHIKV [48] .
Roques et al. developed three types of vaccines and evaluated these againsta non-human primate model. An attenuated sequence of CHIKV (Δ5nsP3), a DNA-launched RNA replicon with encoding of CHIKV envelope proteins (DREP-E) and a DREP-E prime with modified Ankara encoding CHIKV capsid showed protection against a wild type Chikungunya virus. These vaccinations developed both humoral and cellular immunity and proved to be safe without showing any clinical signs [49] . Virus-like particles (VLP) containing the CHIKV envelope and capsid in their surface, as well as recombinant Measles virus with CHIKV polypeptides were able to replicate inside the host cells. This approach can be used to produce vaccine for the prevention of Chikungunya virus infection. [50] .
Application of insect repellants: Insect repellants such as the CDC-approved N,N-diethly-3-methylbenzamide (DEET), picaridin, oil of lemon eucalyptus or para-menthane-3,8-diol, and IR3535 (ethyl butylacetylaminopropionate) can be used to prevent CHIKV transmission. If there is a risk of mosquito transmitted diseases, repellants should be used on exposed skin during the day and also at night. Application frequency of repellants depend on the concentration of the repellants; lower concentration of repellants need to be applied more frequently than higher concentration [51] . DEET is the most preferred insect repellants due to its effectiveness against aggressive biting mosquitoes compared to other non-CDC recommended repellants [52] .
Use of mosquito nets over beds: Vector mosquitoes usually bite during the day and which is why bed nets are necessary while sleeping in the day, especially in CHIKV affected areas [53] . An insecticide impregnated mosquito net is an effective approach against vector mosquitoes [54] .
Protective clothing: Travelers and people in CHIKV affected areas should use appropriate clothing to minimize skin exposure to mosquitoes. Usually, mosquitoes are less attracted towards light color clothing. Loose fitting but tightly woven fabrics are also preferable. Furthermore, insect repellants applied to clothes are longer lasting than when applied to the skin.
Removal of standing water: The mosquitoes transmitting CHIKV usually inhabit stagnant water. Therefore, eliminating stagnant water systems by using sealed containers or covers could prevent the growth of mosquito vectors. People should eliminate standing water around their living quarters and houses to prevent mosquitoes breeding environment. Standing water should be removed at least once a week as mosquitoes need 8-10 days to develop from egg to adult. Even a small amount of stagnant water should be eliminated.
CONCLUSION
In Bangladesh, most of the patients with Chikungunya virus remain undiagnosed or misdiagnosed with dengue virus. This is due to the lack of diagnostic facilities and people presenting similar symptoms caused by the dengue virus. A successful vaccine against Chikungunya virus can be produced in the future, but caution should be taken during its design and development. Since vectors are the most important determinants for spreading Chikungunya virus in the epidemic form, house-to-house measures need to be taken to eliminate vector breeding places by encouraging public awareness [55] .
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